Sponsor

Endocyte

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Endocyte appears in 14 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials14
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

14 shown
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate CancerNCT04597411 · lead sponsor · 2021-04-01
ACTIVE_NOT_RECRUITING
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate CancerNCT03511664 · lead sponsor · 2018-05-29
COMPLETED
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapyNCT03042312 · lead sponsor · 2017-07-12
TERMINATED
Phase 1 of EC1169 In Patients With Recurrent MCRPCNCT02202447 · lead sponsor · 2014-05-01
COMPLETED
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)NCT01953536 · lead sponsor · 2014-04-01
WITHDRAWN
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid TumorsNCT01999738 · lead sponsor · 2013-10-01
COMPLETED
Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung CancerNCT01577654 · lead sponsor · 2011-03-01
COMPLETED
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)NCT01002924 · lead sponsor · 2009-12-31
COMPLETED
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)NCT00511485 · lead sponsor · 2007-08-01
COMPLETED
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate CancerNCT04419402 · collaborator · 2020-08-17
ACTIVE_NOT_RECRUITING
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to ProstatectomyNCT04430192 · collaborator · 2020-08-06
ACTIVE_NOT_RECRUITING
Imaging Activated Macrophages in the LungsNCT03494114 · collaborator · 2018-11-29
TERMINATED
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate CancerNCT03392428 · collaborator · 2018-01-29
COMPLETED
FolateScan in Autoimmune DiseaseNCT00588393 · collaborator · 2006-09-01
COMPLETED

Drugs studied in this sponsor's trials

5 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Endocyte as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
lutetium Lu 177 vipivotide tetraxetan3
cabazitaxel1
docetaxel1
enzalutamide1
folic acid1
lutetium Lu 177 vipivotide tetraxetan RxCUI 2597053 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials cabazitaxel RxCUI 996051 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial enzalutamide RxCUI 1307298 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial folic acid RxCUI 4511 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor9
collaborator5
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.